KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Intangibles: 2014-2024

Historic Change in Intangibles for Vertex Pharmaceuticals (VRTX) over the last 1 years, with Dec 2024 value amounting to $375.4 million.

  • Vertex Pharmaceuticals' Change in Intangibles rose 547.24% to $375.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $245.7 million, marking a year-over-year change of. This contributed to the annual value of $187.7 million for FY2024, which is 223.62% up from last year.
  • As of Q4 2024, Vertex Pharmaceuticals' Change in Intangibles stood at $375.4 million, which was up 4,975.32% from -$7.7 million recorded in Q2 2024.
  • Vertex Pharmaceuticals' 5-year Change in Intangibles high stood at $375.4 million for Q4 2024, and its period low was -$180.0 million during Q1 2024.
  • Moreover, its 2-year median value for Change in Intangibles was $25.1 million (2023), whereas its average is $61.4 million.
  • Data for Vertex Pharmaceuticals' Change in Intangibles shows a peak YoY surged of 547.24% (in 2024) over the last 5 years.
  • Vertex Pharmaceuticals' Change in Intangibles (Quarterly) stood at $58.0 million in 2023, then soared by 547.24% to $375.4 million in 2024.
  • Its Change in Intangibles stands at $375.4 million for Q4 2024, versus -$7.7 million for Q2 2024 and -$180.0 million for Q1 2024.